Associate Professor Mark Dawson, Consultant Haematologist and Head, Cancer Epigenetics Laboratory, Peter MacCallum Cancer Centre, Melbourne, VIC.
Associate Professor Mark Dawson is a consultant haematologist in the department of haematology and Head of the Cancer Epigenetics Laboratory at the Peter MacCallum Cancer Centre.
Associate Professor Dawson’s research interests lie in understanding the epigenetic regulation of normal and malignant haematopoiesis. He is a fellow of the Royal Australasian College of Physicians and Royal College of Pathologists of Australasia. After completing his clinical training in Melbourne, Associate Professor Dawson was awarded the prestigious General Sir John Monash Fellowship and Cambridge Commonwealth Trust Fellowship, which he used to complete his PhD at the University of Cambridge in the United Kingdom. During his PhD, he described a novel signalling pathway involving nuclear JAK2 as a chromatin-modifying enzyme.
Following his PhD, Associate Professor Dawson was awarded the inaugural Wellcome Trust Beit Prize Fellowship to pursue his research into epigenetic regulation of leukaemia stem cells. This research identified a novel therapeutic strategy for acute myeloid leukaemia by targeting the BET bromodomain proteins that function as epigenetic readers. The Cancer Epigenetics Laboratory aims to understand the role of epigenetic regulators in normal and malignant haematopoiesis and to use these insights to identify novel therapies for the treatment of blood cancers.
Associate Professor Dawson’s research is currently supported by a Senior Fellowship from Leukaemia Foundation Australia, the VESKI Innovation Fellowship and a Herman Clinical Fellowship. He is also the recipient of an NHMRC project grant which began March 2014.